I’m back with another semi-regular column tracking the ups and downs in small-cap biotech. Today, I take a look at Bio-Path Holdings (BPTH) and CytoDyn (CYDY). Hint: Red flags hoisted on both. As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.

Shares of Bio-Path Holdings soared an astounding 700 percent over the past two trading sessions. But the company-issued press release that triggered the stock surge omitted some sobering information about its experimental blood cancer drug. Was that misleading? I think it was. Bio-Path’s CEO disagrees. I spoke to him by phone on Thursday night.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy